This is a Prospective, multi‐center, international, randomized controlled, post‐market trial.
Press Releases
August 5, 2019
Impella device now available
This is a Prospective, multi‐center, international, randomized controlled, post‐market trial.
Obesity is a chronic, debilitating, multi-factorial disease that has reached worldwide pandemic proportions. The prevalence of obesity has tripled since the 1980s in many countries of the World Health Organization (WHO) European region. The WHO estimates that by 2015, 2.3 billion people will be overweight and over 700 million will be obese.
This is a Phase 3, randomized, double-blind, placebo-controlled study to evaluate sotatercept when added to background PAH therapy in newly diagnosed intermediate- and high-risk PAH patients.